Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Oramed Pharmaceuticals, Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ORMP
Nasdaq
8731
https://oramed.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Oramed Pharmaceuticals, Inc.
Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation
- Mar 19th, 2024 1:00 pm
Oramed Pharmaceuticals Full Year 2023 Earnings: Beats Expectations
- Mar 9th, 2024 2:32 pm
Oramed Letter to Shareholders
- Feb 20th, 2024 1:30 pm
ORMP: Multiple Potential Applications for Proprietary Oral Protein Delivery Platform
- Jan 24th, 2024 12:27 pm
Oramed Pharmaceuticals (NASDAQ:ORMP) investors are sitting on a loss of 63% if they invested a year ago
- Oct 6th, 2023 1:51 pm
ORMP: Distribution Deals, JVs in Anticipation of Commercializing ORMD-0801
- Oct 5th, 2023 2:13 pm
Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company
- Sep 22nd, 2023 3:38 pm
Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company
- Sep 21st, 2023 10:11 pm
Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.
- Sep 21st, 2023 8:05 pm
Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder
- Sep 13th, 2023 1:00 pm
Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally
- Aug 2nd, 2023 11:45 am
Oramed to Present at the 83rd American Diabetes Association Conference
- Jun 20th, 2023 11:55 am
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
- Jun 17th, 2023 1:54 pm
ORMP: Advancing Development Efforts in China
- May 30th, 2023 3:06 pm
Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit
- May 18th, 2023 11:55 am
Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China
- May 15th, 2023 1:05 pm
Scroll